Novartis India Limited , a prominent player in the Indian pharmaceutical sector, has released its financial results for the second quarter, showcasing significant improvements across key metrics.

Financial Highlights

The company's performance for the quarter demonstrates strong growth and improved profitability:

Key Takeaways

1. Revenue Growth: Novartis India reported a 4.00% year-over-year increase in revenue, reaching ₹903.00 crore for the quarter.

2. EBITDA Performance: The company's EBITDA saw a substantial rise of 33.00%, climbing from ₹179.00 crore to ₹239.00 crore.

3. Margin Expansion: EBITDA margin expanded significantly, improving by 582 basis points to reach 26.44% compared to 20.62% in the same quarter last year.

4. Profit Increase: Net profit grew by 19.00%, rising from ₹204.00 crore to ₹242.00 crore year-over-year.

The robust financial performance indicates Novartis India's strong market position and operational efficiency. The significant improvement in EBITDA and EBITDA margin suggests effective cost management and potentially higher-value product sales.

Corporate Governance

As per the latest LODR (Listing Obligations and Disclosure Requirements) data, Novartis India's Board of Directors met on October 28, 2025, to approve the unaudited financial results for the quarter and half-year ended September 30, 2025. The meeting, which commenced at 11:35 AM (IST) and concluded at 2:45 PM (IST), also included a review of the Limited Review Report issued by the company's Statutory Auditors.

This timely disclosure aligns with regulatory requirements and demonstrates Novartis India's commitment to transparency and corporate governance standards.

Investors and stakeholders can access the detailed financial results and the Limited Review Report on the company's official website at www.novartis.com/in-en/ .

As Novartis India continues to navigate the dynamic pharmaceutical landscape, these results reflect its resilience and ability to drive growth in a competitive market. Stakeholders will likely keep a close eye on how the company maintains this momentum in the coming quarters.

Novartis India Limited , a prominent player in the pharmaceutical sector, has released its financial results for the first quarter, showcasing a mixed performance. The company also announced the appointment of new cost auditors for the upcoming financial year.

Financial Performance

Novartis India reported a revenue from operations of ₹875.50 crore for the quarter. This figure represents a slight decline of 5.1% compared to ₹922.90 crore in the same quarter of the previous year. However, it shows a modest increase of 4.4% from the ₹838.80 crore reported in the preceding quarter.

Despite the marginal dip in revenue, the company's profitability saw an improvement. The profit for the period stood at ₹276.20 crore, marking a 7.3% increase from ₹257.40 crore in the corresponding quarter last year. However, it's worth noting that this figure is slightly lower than the ₹293.00 crore profit reported in the previous quarter.

The company's earnings per share (EPS) for the quarter was reported at ₹11.19.

Key Financial Metrics

Appointment of Cost Auditors

In a significant corporate development, Novartis India's Board of Directors has approved the appointment of M/s. D.C. Dave & Co. as the company's Cost Auditors for the upcoming fiscal year. The firm, with registration number 000611, is recognized as a leading practice of Cost Accountants with extensive experience in cost audit, compliance, assurance, and consulting services.

The Board has set the remuneration for the Cost Auditors at ₹1.50 lakh, plus applicable taxes. This appointment and the proposed remuneration are subject to ratification by the shareholders through a postal ballot.

Postal Ballot Notice

The company's Board has also approved a draft notice for a postal ballot to seek shareholders' approval on the ratification of the remuneration payable to the newly appointed Cost Auditors. This move is in compliance with Section 148 of the Companies Act, 2013.

Segment Information

Novartis India continues to operate in a single business segment, focusing solely on pharmaceuticals. This strategic focus allows the company to leverage its expertise and resources in the pharmaceutical domain.

The financial results, approved by the Board of Directors, have been subject to a limited review by the company's statutory auditors. As Novartis India navigates through the evolving pharmaceutical landscape, stakeholders will be keenly watching how these financial results and corporate decisions shape the company's future trajectory.